Skip to main content
Fig. 4 | World Journal of Surgical Oncology

Fig. 4

From: Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study

Fig. 4

CEA and CA19-9 at different stages. a CEA and CA19-9 level change in the successful conversion group. A, B, and C represent the CEA level at baseline, before and after operation, respectively. F, G, and H represent the CA19-9 level at baseline, before and after operation, respectively. b CEA and CA19-9 level change in the failed group. D and E represent the CEA level at baseline and at the end of conversion therapy, respectively. I and J represent the CA19-9 level at baseline and at the end of conversion therapy, respectively. (***p < 0.001; ns, no significance)

Back to article page